BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

Nora Liebers^{1

2}, Tobias Roider^{1

3}, Jan-Paul Bohn⁴, Isabella Haberbosch¹, Andreas Pircher⁴, Barbara Ferstl⁵, Monika Ebnöther⁶, Clemens-Martin Wendtner⁷, Claire Dearden⁸, George A Follows⁹, Anthony D Ho¹, Carsten Müller-Tidow^{1

2}, Peter Dreger¹, Xavier Troussard¹⁰, Thorsten Zenz¹¹, Sascha Dietrich^{12

13

14}

Affiliations

¹ Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
² National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
³ European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
⁴ Department of Internal Medicine V, Division of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
⁵ Department of Medicine 5, Universitätsklinikum Erlangen, Erlangen, Germany.
⁶ Department of Hematology and Oncology, St. Claraspital, Basel, Switzerland.
⁷ Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany.
⁸ The Royal Marsden Hospital, London, UK.
⁹ Department of Hematology, Addenbrookes Hospital, Cambridge, UK.
¹⁰ CHU de Caen, laboratoire d'hématologie, Caen, France.
¹¹ Division of Medical Oncology and Hematology, Universitätsspital Zürich, Zürich, Switzerland.
¹² Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.
¹³ National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.
¹⁴ European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.

Nora Liebers et al. Leukemia. 2020 May.

. 2020 May;34(5):1454-1457.

doi: 10.1038/s41375-019-0646-y. Epub 2019 Nov 18.

¹ Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
² National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
³ European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
⁴ Department of Internal Medicine V, Division of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
⁵ Department of Medicine 5, Universitätsklinikum Erlangen, Erlangen, Germany.
⁶ Department of Hematology and Oncology, St. Claraspital, Basel, Switzerland.
⁷ Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Hospital Munich-Schwabing, Munich, Germany.
⁸ The Royal Marsden Hospital, London, UK.
⁹ Department of Hematology, Addenbrookes Hospital, Cambridge, UK.
¹⁰ CHU de Caen, laboratoire d'hématologie, Caen, France.
¹¹ Division of Medical Oncology and Hematology, Universitätsspital Zürich, Zürich, Switzerland.
¹² Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.
¹³ National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.
¹⁴ European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. sascha.dietrich@med.uni-heidelberg.de.

No abstract available

References

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. - DOI
1. Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60. - DOI
1. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–40. - DOI
1. Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016;127:2847–55. - DOI
1. Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015;373:1733–47. - DOI